AR094762A1 - Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo - Google Patents
Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroariloInfo
- Publication number
- AR094762A1 AR094762A1 ARP140100441A ARP140100441A AR094762A1 AR 094762 A1 AR094762 A1 AR 094762A1 AR P140100441 A ARP140100441 A AR P140100441A AR P140100441 A ARP140100441 A AR P140100441A AR 094762 A1 AR094762 A1 AR 094762A1
- Authority
- AR
- Argentina
- Prior art keywords
- cr5ar5b
- alkyl
- optionally substituted
- cycloalkyl
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
También se describen composiciones farmacéuticas, métodos de tratamiento, métodos de síntesis e intermediarios correspondientes. Reivindicación 1: Un compuesto de la fórmula (1) en donde R¹ es hidrógeno o metilo, en donde el metilo se sustituye opcionalmente con uno a tres flúor; R² es un heteroarilo de 5 a 10 miembros, que tiene de 1 a 4 heteroátomos seleccionados independientemente de N, O ó S, en donde al menos uno de los heteroátomos es N y en donde N se sustituye opcionalmente con R⁴; y en donde el heteroarilo de 5 a 10 miembros se sustituye opcionalmente sobre carbón con uno a tres R³; R³, en cada caso, se selecciona independientemente del grupo que consiste en halógeno, hidroxi, ciano, alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, cicloalcoxi C₃₋₆, cicloalcoxi C₃₋₆-(CR⁵ᵃR⁵ᵇ)ₘ-, cicloalquil C₃₋₆-(CR⁵ᵃR⁵ᵇ)ₙ-O-, -(CR⁵ᵃR⁵ᵇ)ₘ-cicloalquilo C₃₋₆ o -(CR⁵ᵃR⁵ᵇ)ₘ-(heterocicloalquilo de 4 a 6 miembros); en donde cada uno de alquilo C₁₋₆, alcoxi C₁₋₆ o alcoxi C₁₋₆-alquilo C₁₋₆ se sustituye opcionalmente con 1 a 3 flúor y en donde el cicloalquilo C₃₋₆, cicloalcoxi C₃₋₆ y las porciones (heterocicloalquilo de 4 a 6 miembros) se sustituyen opcionalmente con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en flúor, metilo, fluorometilo, difluorometilo o trifluorometilo; R⁴ es hidrógeno, alquilo C₁₋₆, -(CR⁵ᵃR⁵ᵇ)ₘ-cicloalquilo C₃₋₆ o -(CR⁵ᵃR⁵ᵇ)ₘ-(heterocicloalquilo de 4 a 6 miembros); en donde cada uno de alquilo C₁₋₆, cicloalquilo C₃₋₆ y las porciones -(heterocicloalquilo de 4 a 6 miembros) se sustituyen opcionalmente con 1 a 3 sustituyentes seleccionados independientemente de flúor, metilo, trifluorometilo, metoxi o trifluorometoxi; R⁵ᵃ y R⁵ᵇ son independientemente hidrógeno, metilo, fluorometilo, difluorometilo, trifluorometilo o metoxi; m, en cada caso, es independientemente 0, 1 ó 2; y n es 1, 2 ó 3; o un tautómero de aquel, o una sal aceptable desde el punto de vista farmacéutico del compuesto o tautómero.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361764185P | 2013-02-13 | 2013-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR094762A1 true AR094762A1 (es) | 2015-08-26 |
Family
ID=50114462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100441A AR094762A1 (es) | 2013-02-13 | 2014-02-12 | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo |
Country Status (8)
Country | Link |
---|---|
US (3) | US8865706B2 (es) |
EP (1) | EP2956458B1 (es) |
JP (1) | JP2016507551A (es) |
AR (1) | AR094762A1 (es) |
CA (1) | CA2897678A1 (es) |
TW (1) | TW201443064A (es) |
UY (1) | UY35320A (es) |
WO (1) | WO2014125394A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
ES2585262T3 (es) * | 2012-05-04 | 2016-10-04 | Pfizer Inc | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 |
CA2882389A1 (en) | 2012-09-20 | 2014-03-27 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
CA2893256A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
US9403846B2 (en) | 2012-12-19 | 2016-08-02 | Pfizer Inc. | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
CA2897678A1 (en) * | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
MA39866A (fr) | 2014-04-10 | 2017-02-15 | Pfizer | Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle |
WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
AU2016325665A1 (en) | 2015-09-24 | 2018-03-08 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides |
EP3497105A1 (en) * | 2016-08-11 | 2019-06-19 | Eli Lilly And Company | Aminothiazines and their use as bace1 inhibitors |
CN107235978B (zh) * | 2017-08-01 | 2019-05-21 | 上海泓博智源医药股份有限公司 | 一种abt-199中间体的制备方法 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017197A1 (en) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTIBODY AGAINST β-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF |
AU4149696A (en) * | 1994-11-15 | 1996-06-06 | Merck & Co., Inc. | Substituted heterocycles as inhibitors of nitric oxide synthase |
ES2312185T3 (es) | 1997-04-09 | 2009-02-16 | Intellect Neurosciences, Inc. | Anticuerpos recombinantes especificos contra las terminaciones de amiloide beta, adn que codifica y procedimientos de utilizacion de los mismos. |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
US6929808B2 (en) | 2000-11-03 | 2005-08-16 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
PT1481992T (pt) | 2000-02-24 | 2017-01-02 | Lilly Co Eli | Anticorpos humanizados que sequestram péptido beta-amiloide |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
GEP20053710B (en) | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
JP2005503789A (ja) | 2001-08-17 | 2005-02-10 | イーライ・リリー・アンド・カンパニー | 抗Aβ抗体 |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
AU2003248354A1 (en) | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Acc inhibitors |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
KR20050071564A (ko) | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물 |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
MXPA05013770A (es) | 2003-06-19 | 2006-03-08 | Pfizer Prod Inc | Antagonista de neuroquinina 1. |
US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
WO2005080361A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
PL1753748T3 (pl) | 2004-05-12 | 2010-01-29 | Pfizer Prod Inc | Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV |
BRPI0510273A (pt) | 2004-05-25 | 2007-10-30 | Pfizer Prod Inc | derivados de tetraazabenzo[e]azuleno e análogos destes |
NZ552480A (en) | 2004-07-30 | 2010-01-29 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods of using same |
EP1827493A4 (en) | 2004-12-22 | 2009-09-30 | Univ St Louis | USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
DK1881985T3 (da) | 2005-05-12 | 2011-02-14 | Pfizer | Vandfrie krystalliske former af N-Y1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-D]pyrimidin-3-carbonyl¨methansulfonamid |
CA2603830A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | PYRIDINE [2,3-B] PYRAZINONES |
WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
DE602006018301D1 (de) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
DE102005040694A1 (de) | 2005-08-27 | 2007-03-01 | Schaeffler Kg | Ventiltrieb mit mechanischer Ventilspieleinstellung und Verfahren zu dessen Montage |
ES2476027T3 (es) | 2005-10-25 | 2014-07-11 | Shionogi & Co., Ltd. | Derivados de aminodihidrotriazina |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | H3受容体のテトラリン拮抗薬 |
CA2648852C (en) | 2006-04-20 | 2012-12-11 | Pfizer Products Inc. | Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
RS51885B (en) | 2006-04-21 | 2012-02-29 | Pfizer Products Inc. | PYRIDIN [3,4-b] PYRAZINNES |
WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
ATE552262T1 (de) | 2006-11-29 | 2012-04-15 | Pfizer Prod Inc | Spiroketone als inhibitoren von acetyl-coa- carboxylase |
MX2009007782A (es) | 2007-01-22 | 2009-07-31 | Pfizer Prod Inc | Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma. |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
US9321730B2 (en) | 2007-08-21 | 2016-04-26 | The Hong Kong Polytechnic University | Method of making and administering quinoline derivatives as anti-cancer agents |
SI2233474T1 (sl) | 2008-01-18 | 2015-11-30 | Eisai R&D Management Co., Ltd. | Kondenziran derivat aminodihidrotiazina |
CA2724774C (en) | 2008-05-28 | 2013-06-25 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
US20110130365A1 (en) | 2008-07-29 | 2011-06-02 | Benbow John W | Fluorinated Heteroaryls |
EP2334687B9 (en) | 2008-08-28 | 2012-08-08 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
CN102171221B (zh) | 2008-09-30 | 2013-11-06 | 卫材R&D管理有限公司 | 新的稠合的氨基二氢噻嗪衍生物 |
WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
PT2406253E (pt) | 2009-03-11 | 2013-09-11 | Pfizer | Derivados de benzofuranilo utilizados como inibidores de glucocinase |
EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
JP2012526097A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
US20100285145A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc | Gpr 119 modulators |
CN102459222B (zh) | 2009-06-05 | 2014-06-04 | 辉瑞大药厂 | 用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物 |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
WO2011071109A1 (ja) * | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US8598161B2 (en) | 2011-05-24 | 2013-12-03 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
JP6043355B2 (ja) * | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
ES2585262T3 (es) | 2012-05-04 | 2016-10-04 | Pfizer Inc | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 |
CA2893256A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
CA2897678A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
CN111772834B (zh) | 2014-03-21 | 2022-07-15 | 阿莱恩技术有限公司 | 具有弹性体的分段的正畸矫正器 |
-
2014
- 2014-02-03 CA CA2897678A patent/CA2897678A1/en not_active Abandoned
- 2014-02-03 JP JP2015556596A patent/JP2016507551A/ja active Pending
- 2014-02-03 WO PCT/IB2014/058760 patent/WO2014125394A1/en active Application Filing
- 2014-02-03 EP EP14704927.4A patent/EP2956458B1/en not_active Not-in-force
- 2014-02-11 TW TW103104416A patent/TW201443064A/zh unknown
- 2014-02-12 UY UY0001035320A patent/UY35320A/es not_active Application Discontinuation
- 2014-02-12 AR ARP140100441A patent/AR094762A1/es unknown
- 2014-02-12 US US14/178,470 patent/US8865706B2/en not_active Expired - Fee Related
- 2014-08-21 US US14/464,935 patent/US9045499B2/en not_active Expired - Fee Related
-
2015
- 2015-04-23 US US14/694,288 patent/US9192612B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2016507551A (ja) | 2016-03-10 |
US20140364426A1 (en) | 2014-12-11 |
US20150224110A1 (en) | 2015-08-13 |
EP2956458A1 (en) | 2015-12-23 |
US20140228356A1 (en) | 2014-08-14 |
UY35320A (es) | 2014-09-30 |
CA2897678A1 (en) | 2014-08-21 |
EP2956458B1 (en) | 2017-08-09 |
US8865706B2 (en) | 2014-10-21 |
TW201443064A (zh) | 2014-11-16 |
US9192612B2 (en) | 2015-11-24 |
US9045499B2 (en) | 2015-06-02 |
WO2014125394A1 (en) | 2014-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
AR090928A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina heterociclicos sustituidos | |
AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
CR20160548A (es) | Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1 | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
ES2721031T3 (es) | Compuestos de dihidroisoquinolinona sustituidos | |
AR098912A1 (es) | Inhibidores de syk | |
AR094857A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
EA201500875A1 (ru) | СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |